Feeds:
Posts
Comments

Archive for the ‘New prostate drugs’ Category

URO TODAY: Swedish research shows a new treatment for advanced prostate cancer, the gonadotrophin-releasing hormone antagonist/receptor blocker Degarelix, is well tolerated, with no systemic allergic reactions. READ MORE>

This new agent represents an important pharmacological development in the hormonal treatment of prostate cancer.

Read Full Post »

ADVANCED PROSTATE CANCER: A new drug has shown promise in prolonging life and reducing pain for men with advanced prostate cancer and for whom chemotherapy in not working.  READ MORE>

Once we have failed docetaxel therapy (chemo therapy) we have very few options available to control advanced prostate cancer.

There is a recent report about a clinical trial using a new potential drug, Patupilone.

Patupilone has shown some evidence that it exhibits a limited positive effect in the pre-clinical setting in taxane resistant models of prostate cancer, meaning prostate cancer that does not respond or no longer responds to taxotere therapy.

Read Full Post »

URO TODAY: A number of promising new drugs and treatments targeting prostate cancer progression are in clinical trials and have the potential to provide novel treatment options for advanced cancer in the near future. READ MORE>

Read Full Post »

JULY 12: ASSOCIATED PRESS: Johnson & Johnson says it has completed its $US893.7 million acquisition of Cougar Biotechnology Inc, a development stage company that is testing a potential vaccine for prostate cancer. Los Angeles-based Cougar is conducting two late stage clinical trials of abiraterone acetate as a treatment for prostate cancer. READ MORE>

Read Full Post »

JUNE 25: REUTERS: OncoGenex Pharmaceuticals Inc says it has reached an agreement with US health regulators to amend the design of a late-stage trial of its lead prostate cancer drug, OGX-011. READ MORE>

Read Full Post »

JUNE 24: WALL ST JOURNAL: Shares of Medarex Inc. (MEDX) surged Monday on news that two patients taking the biopharmaceutical company’s prostate cancer treatment in a mid-stage trial are now cancer free. READ MORE>

Read Full Post »

JUNE 20: DINTZ.COM: Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardised hormone treatment and radiation therapy. The men were participating in a clinical trial of an immuno-therapeutic agent called MDX-010 or ipilimumab. READ MORE>

Read Full Post »

JUNE 19: REUTERS HEALTH: Abiraterone acetate leads to significant declines in prostate-specific antigen (PSA) in men with castration-resistant prostate cancer, an aggressive form of the disease. READ MORE>

Read Full Post »

JUNE 19: NEW PROSTATE CANCER INFOLINK: It may be too early to make decisions about the real clinical utility of degarelix. READ MORE>

Read Full Post »

JUNE 11: SEEKING ALPHA.COM: A groundbreaking new treatment for prostate cancer, Provenge, will likely receive US Food and Drug Administration approval and become widely available just as the first Baby Boomers reach 65 in 2010.  READ MORE>

Read Full Post »

« Newer Posts - Older Posts »